Quantcast

BioNTech, Fosun Pharma, Phizer working on COVID-19 vaccine. Clinical testing in Germany in April

BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.

Read more

Pfizer’s study of investigational Oral JAK1 candidate in Abrocitinibfor Severe Atopic Dermatitis hits targets

Pfizer’s study of investigational Oral JAK1 candidate in Abrocitinibfor Severe Atopic Dermatitis hits targets achieves all co-primary and key secondary endpoints, as safety results show both doses of abrocitinib consistent with prior clinical trial experiences.

Read more